4D Molecular Therapeutics Inc Asset Resilience Ratio
4D Molecular Therapeutics Inc asset resilience ratio. 4D Molecular Therapeutics Inc (FDMT) has an Asset Resilience Ratio of 60.42% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See FDMT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of 4D Molecular Therapeutics Inc (2020–2025)
Asset resilience ratio of 4D Molecular Therapeutics Inc from 2020 to 2025. This chart shows how 4D Molecular Therapeutics Inc's Asset Resilience Ratio has changed over time. Read 4D Molecular Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down 4D Molecular Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is 4D Molecular Therapeutics Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $342.41 Million | 60.42% |
| Total Liquid Assets | $342.41 Million | 60.42% |
Asset Resilience Insights
- Very High Liquidity: 4D Molecular Therapeutics Inc maintains exceptional liquid asset reserves at 60.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
4D Molecular Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare 4D Molecular Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
4D Molecular Therapeutics Inc Asset Resilience Ratio by Year (2020–2025)
4D Molecular Therapeutics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for 4D Molecular Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.42% | $342.41 Million | $566.71 Million | +11.25pp |
| 2024-12-31 | 49.17% | $275.54 Million | $560.38 Million | +37.66pp |
| 2023-12-31 | 11.51% | $39.12 Million | $339.89 Million | -50.05pp |
| 2022-12-31 | 61.56% | $161.20 Million | $261.85 Million | +34.75pp |
| 2021-12-31 | 26.81% | $94.78 Million | $353.49 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $288.33 Million | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more